PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18398611-2 2009 An individual"s response to fludarabine may be influenced by the amount of CD4(+) and CD8(+) T-lymphocyte suppression. fludarabine 28-39 CD4 molecule Homo sapiens 75-78 20463575-2 2010 Prolonged CD4 lymphopenia may develop in patients with chronic lymphocytic leukemia who receive fludarabine. fludarabine 96-107 CD4 molecule Homo sapiens 10-13 20857100-7 2011 Analysis of peripheral blood samples from patients prior and during fludarabine/cyclophosphamide therapy revealed rapid and sustained reduction of tumour cells but also of CD4(+) and CD8(+) T cells. fludarabine 68-79 CD4 molecule Homo sapiens 172-175 15914560-0 2005 Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. fludarabine 143-154 CD4 molecule Homo sapiens 48-51 19270751-15 2009 Surprisingly, fludarabine also increased the relative percentage of CD4+ T cells expressing the regulatory protein Foxp3. fludarabine 14-25 CD4 molecule Homo sapiens 68-71 18443965-1 2008 We report a case of a previously healthy 31 year old woman diagnosed with Stage IIIA follicular lymphoma treated with fludarabine in combination with cyclophosphamide and rituximab who presented seven years after the completion of therapy with CD4 count depression, panhypogammaglobulinema and a history of recurrent sinus infections. fludarabine 118-129 CD4 molecule Homo sapiens 244-247 17588483-4 2007 A high percentage of CD4 T cells expressed high levels of CD25 in recipients of all protocols, except the only protocol to include fludarabine, early post-HCT. fludarabine 131-142 CD4 molecule Homo sapiens 21-24 18004569-3 2008 METHODS: Intracellular accumulation of fludarabine triphosphate (F-ara-ATP), the active metabolite of fludarabine, was measured in CD4(+) and CD8(+) T-lymphocytes isolated from healthy volunteers, which were treated in vitro with fludarabine alone, and in the presence of either imatinib or NBMPR, a known hENT inhibitor. fludarabine 39-50 CD4 molecule Homo sapiens 131-134 18004569-3 2008 METHODS: Intracellular accumulation of fludarabine triphosphate (F-ara-ATP), the active metabolite of fludarabine, was measured in CD4(+) and CD8(+) T-lymphocytes isolated from healthy volunteers, which were treated in vitro with fludarabine alone, and in the presence of either imatinib or NBMPR, a known hENT inhibitor. fludarabine 102-113 CD4 molecule Homo sapiens 131-134 14609743-0 2003 In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine. fludarabine 59-70 CD4 molecule Homo sapiens 27-30 14609743-1 2003 Administration of the adenosine analogue fludarabine (FLU) in vivo induces a profound and prolonged T lymphopenia which mainly affects CD4(+) cells. fludarabine 41-52 CD4 molecule Homo sapiens 135-138 14609743-1 2003 Administration of the adenosine analogue fludarabine (FLU) in vivo induces a profound and prolonged T lymphopenia which mainly affects CD4(+) cells. fludarabine 54-57 CD4 molecule Homo sapiens 135-138 14609743-3 2003 Contrasting with observations in vivo, our results showed that treatment of peripheral blood mononuclear cells with FLU induced a higher level of apoptosis in CD8(+) than in CD4(+) T lymphocytes. fludarabine 116-119 CD4 molecule Homo sapiens 174-177 14609743-4 2003 This increased sensitivity of CD8(+) T cells to FLU was observed in samples from both, healthy donors and B cell chronic lymphocytic leukemia patients, and resulted in higher CD4:CD8 ratios in FLU-treated than in untreated cultures (P<0.01). fludarabine 48-51 CD4 molecule Homo sapiens 175-178 14609743-4 2003 This increased sensitivity of CD8(+) T cells to FLU was observed in samples from both, healthy donors and B cell chronic lymphocytic leukemia patients, and resulted in higher CD4:CD8 ratios in FLU-treated than in untreated cultures (P<0.01). fludarabine 193-196 CD4 molecule Homo sapiens 175-178 14609743-8 2003 These results favor the view that decreased CD4:CD8 ratios in FLU-treated patients should be attributed to differences in cell recovery and/or homing between T cell subsets. fludarabine 62-65 CD4 molecule Homo sapiens 44-47 14583577-7 2003 Marked peripheral lymphopenia involving naive (CD4(+) CD45RA(+)) and memory (CD4(+) CD45RO(+)) T cells, CD8(+) T cells, and B cells was seen in fludarabine treated patients. fludarabine 144-155 CD4 molecule Homo sapiens 47-50 14583577-7 2003 Marked peripheral lymphopenia involving naive (CD4(+) CD45RA(+)) and memory (CD4(+) CD45RO(+)) T cells, CD8(+) T cells, and B cells was seen in fludarabine treated patients. fludarabine 144-155 CD4 molecule Homo sapiens 54-57 14569558-7 2003 Fludarabine exposure markedly reduced the CD4+CD44(low)-naive donor T-cell population within 48 hours of transplantation and altered the relative representation of cytokine-producing CD4+ T cells, consistent with T-helper type 2 polarization. fludarabine 0-11 CD4 molecule Homo sapiens 42-45 14569558-7 2003 Fludarabine exposure markedly reduced the CD4+CD44(low)-naive donor T-cell population within 48 hours of transplantation and altered the relative representation of cytokine-producing CD4+ T cells, consistent with T-helper type 2 polarization. fludarabine 0-11 CD4 molecule Homo sapiens 46-49 14569558-9 2003 The results suggest that fludarabine reduces the GVHD potential of donor lymphocytes through effects on a CD4+CD44(low) T-cell population, with less effect on alloreactive T cells and CD4+CD44(high) memory T cells that are able to mediate GVL effects. fludarabine 25-36 CD4 molecule Homo sapiens 106-109 14569558-9 2003 The results suggest that fludarabine reduces the GVHD potential of donor lymphocytes through effects on a CD4+CD44(low) T-cell population, with less effect on alloreactive T cells and CD4+CD44(high) memory T cells that are able to mediate GVL effects. fludarabine 25-36 CD4 molecule Homo sapiens 110-113 12707730-4 2003 We report the case of a 66-year-old man with CD4/CD8 double negative SPTCL who achieved a complete remission with single-agent fludarabine. fludarabine 127-138 CD4 molecule Homo sapiens 45-48 21590098-3 1997 In contrast, other new nucleoside analogues such as the purine antimetabolite fludarabine lead to a significant alteration of the CD4/CD8 lymphocyte ratio associated with an increased risk for opportunistic infections. fludarabine 78-89 CD4 molecule Homo sapiens 130-133 8353071-13 1993 The high infection rate may be due not only to hypogammaglobulinaemia or fludarabine-induced granulocytopenia but also to a remarkable decrease of CD4(+)-cells during fludarabine therapy. fludarabine 167-178 CD4 molecule Homo sapiens 147-150 8353071-17 1993 However, fludarabine has a remarkable suppressive effect on T-lymphocytes, predominantly CD4(+)-lymphocytes. fludarabine 9-20 CD4 molecule Homo sapiens 89-92 9543067-1 1998 Fludarabine has been associated with an increased risk of opportunistic infections, possibly related to the induction of profound CD4+ lymphopenia. fludarabine 0-11 CD4 molecule Homo sapiens 130-133 8599867-8 1996 Phenotypic analysis of the peripheral mononuclear cells in 34 consecutive CLL patients revealed a marked reduction in CD5/CD20 and CD4 cell numbers after three courses of fludarabine with less effect on CD8 and CD56 cells. fludarabine 171-182 CD4 molecule Homo sapiens 131-134 7632936-3 1995 In addition, immunologic deficits may persist even in patients in complete remission; lymphopenia, predominantly involving the CD4 population, is universal after fludarabine therapy. fludarabine 162-173 CD4 molecule Homo sapiens 127-130 7694371-10 1993 A significant concern in patients with CLL treated with fludarabine is a decrease in the CD4 and CD8 counts. fludarabine 56-67 CD4 molecule Homo sapiens 89-92 8400226-10 1993 With therapy, CD4 levels were uniformly depressed from a median 1,015/microL pretreatment to a median 159/microL after 3 months of fludarabine therapy. fludarabine 131-142 CD4 molecule Homo sapiens 14-17 1354425-9 1992 A dramatic reduction in CD4 counts occurred in patients after fludarabine and prednisone treatment and coincided with the development of listeriosis. fludarabine 62-73 CD4 molecule Homo sapiens 24-27 25983023-2 2015 Fludarabine"s metabolite, 9-beta-D-arabinofuranosyl-2-fluoroadenine (F-ara-A), undergoes cellular uptake and activation to form the active cytotoxic metabolite fludarabine triphosphate (F-ara-ATP), which inhibits cellular DNA synthesis in CD4(+) and CD8(+) cells. fludarabine 0-11 CD4 molecule Homo sapiens 239-242 25983023-2 2015 Fludarabine"s metabolite, 9-beta-D-arabinofuranosyl-2-fluoroadenine (F-ara-A), undergoes cellular uptake and activation to form the active cytotoxic metabolite fludarabine triphosphate (F-ara-ATP), which inhibits cellular DNA synthesis in CD4(+) and CD8(+) cells. fludarabine 26-67 CD4 molecule Homo sapiens 239-242 25983023-2 2015 Fludarabine"s metabolite, 9-beta-D-arabinofuranosyl-2-fluoroadenine (F-ara-A), undergoes cellular uptake and activation to form the active cytotoxic metabolite fludarabine triphosphate (F-ara-ATP), which inhibits cellular DNA synthesis in CD4(+) and CD8(+) cells. fludarabine 69-76 CD4 molecule Homo sapiens 239-242 21985361-6 2011 Patients undergoing treatment with fludarabine demonstrated a transient increase in the percentage of CD4+ FoxP3+ T cells, but this reduced to normal levels post-treatment. fludarabine 35-46 CD4 molecule Homo sapiens 102-105